Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Carolina Wellness News.
Press releases published on September 2, 2025
Dianabol (Dbol) Pills 2025: DBal Max Launch Dianabol Anabolic Legal Steroid Alternatives for Beginners Dosage Usage, Benefits & Results
GlobeNewswire
·
September 2, 2025
new york, Sept. 02, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York, (Dbal Max) introduced Dianabol Steroids - the pioneering muscle gain supplement designed to deliver quick, heavy gains rapidly, in safety. Designed as the all-natural, legally …
Military Veterans Join Virtue Recovery to Expand Community Outreach with Hope and Support
GlobeNewswire
·
September 2, 2025
LAS VEGAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Virtue Recovery is proud to announce the expansion of its Business Development Team with the addition of two U.S. military veterans: Adam Khosroabadi, U.S. Marine Corps Veteran, and Chauncy Nash, U.S. Army …
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
GlobeNewswire
·
September 2, 2025
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001 …
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
GlobeNewswire
·
September 2, 2025
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
GlobeNewswire
·
September 2, 2025
TAIPEI, Taiwan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface …
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
GlobeNewswire
·
September 2, 2025
Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with potential for more than $400 million …
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
GlobeNewswire
·
September 2, 2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial builds on Phase 2a double-blind, …
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
GlobeNewswire
·
September 2, 2025
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; …
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
GlobeNewswire
·
September 2, 2025
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company pioneering a transformative approach …
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
GlobeNewswire
·
September 2, 2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the …
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
GlobeNewswire
·
September 2, 2025
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a …